NASDAQ:RPTX

Repare Therapeutics (RPTX) Stock Price, News & Analysis

$3.26
+0.11 (+3.49%)
(As of 04/22/2024 ET)
Today's Range
$3.09
$3.40
50-Day Range
$3.02
$7.20
52-Week Range
$2.98
$13.85
Volume
109,320 shs
Average Volume
114,660 shs
Market Capitalization
$120.62 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.33

Repare Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
431.7% Upside
$17.33 Price Target
Short Interest
Bearish
2.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.59mentions of Repare Therapeutics in the last 14 days
Based on 5 Articles This Week
Insider Trading
Selling Shares
$54,037 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($2.74) to ($3.08) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.01 out of 5 stars

Medical Sector

357th out of 909 stocks

Pharmaceutical Preparations Industry

159th out of 422 stocks

RPTX stock logo

About Repare Therapeutics Stock (NASDAQ:RPTX)

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.

RPTX Stock Price History

RPTX Stock News Headlines

SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
SHOCKING Crypto Leak…
A shocking leak has revealed tech giant Microsoft's plans to add crypto support to future products. If the plans in these leaked internal documents pan out, we could see prices skyrocket for Bitcoin, Ethereum, XRP and MORE… The coupling of gaming and cryptocurrency could absolutely transform digital finance as we know it in 2024.
RPTX Apr 2024 7.500 call
RPTX Jul 2024 7.500 call
Recap: Repare Therapeutics Q4 Earnings
RPTX Mar 2024 7.500 call
See More Headlines
Receive RPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/22/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:RPTX
Fax
N/A
Employees
179
Year Founded
2016

Price Target and Rating

Average Stock Price Target
$17.33
High Stock Price Target
$25.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+431.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-93,800,000.00
Net Margins
-183.43%
Pretax Margin
-201.79%

Debt

Sales & Book Value

Annual Sales
$51.13 million
Book Value
$5.03 per share

Miscellaneous

Free Float
26,456,000
Market Cap
$120.62 million
Optionable
Optionable
Beta
0.57

Social Links

Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Mr. Lloyd Mitchell SegalMr. Lloyd Mitchell Segal (Age 60)
    President, CEO & Director
    Comp: $913.39k
  • Dr. Michael Zinda Ph.D. (Age 53)
    Executive VP & Chief Scientific Officer
    Comp: $641.53k
  • Dr. Maria Koehler M.D. (Age 67)
    Ph.D., Executive VP & Chief Medical Officer
    Comp: $682.8k
  • Dr. Daniel Durocher Ph.D.
    Co-Founder
  • Dr. Frank Sicheri Ph.D.
    Co-Founder
  • Dr. Agnel Sfeir Ph.D.
    Co-Founder
  • Mr. Steve Forte (Age 45)
    Executive VP & CFO
    Comp: $608.52k
  • Mr. Daniel Belanger
    Executive Vice President of Human Resource
  • Mr. Cameron Black
    Executive Vice President of Discovery
  • Dr. Kim A. Seth Ph.D.
    Executive VP & Chief Business Officer

RPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Repare Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RPTX shares.
View RPTX analyst ratings
or view top-rated stocks.

What is Repare Therapeutics' stock price target for 2024?

4 Wall Street research analysts have issued twelve-month target prices for Repare Therapeutics' shares. Their RPTX share price targets range from $10.00 to $25.00. On average, they expect the company's stock price to reach $17.33 in the next year. This suggests a possible upside of 431.7% from the stock's current price.
View analysts price targets for RPTX
or view top-rated stocks among Wall Street analysts.

How have RPTX shares performed in 2024?

Repare Therapeutics' stock was trading at $7.30 on January 1st, 2024. Since then, RPTX shares have decreased by 55.3% and is now trading at $3.26.
View the best growth stocks for 2024 here
.

When is Repare Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our RPTX earnings forecast
.

How were Repare Therapeutics' earnings last quarter?

Repare Therapeutics Inc. (NASDAQ:RPTX) issued its quarterly earnings data on Wednesday, February, 28th. The company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.11. The firm earned $13.05 million during the quarter, compared to the consensus estimate of $15.92 million. Repare Therapeutics had a negative net margin of 183.43% and a negative trailing twelve-month return on equity of 39.82%.

What ETF holds Repare Therapeutics' stock?

ARK Genomic Revolution ETF holds 2,612,292 shares of RPTX stock, representing 0.68% of its portfolio.

What other stocks do shareholders of Repare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AES (AES), Autodesk (ADSK) and

When did Repare Therapeutics IPO?

Repare Therapeutics (RPTX) raised $126 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.

Who are Repare Therapeutics' major shareholders?

Repare Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.83%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Steve Forte, Thomas Civik and Todd Foley.
View institutional ownership trends
.

How do I buy shares of Repare Therapeutics?

Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:RPTX) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners